Evonetix: Evonetix closes $24 million financing

Evonetix, the synthetic biology company bringing semiconductor technology to DNA synthesis, has completed a USD $24 million financing round, extending its total series B funding to over USD $54 million (circa GB £44 million). This fundraise was led by existing investor Foresite Capital, with Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence also participating in the round.